Navigation Links
Heritage Pharma Announces The Return Of Tetracycline HCI Capsules
Date:10/21/2013

EATONTOWN, N.J., Oct. 21, 2013 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") announced the immediate availability of Tetracycline HCl Capsules, USP in 250 and 500 mg strengths.  This product is the AB rated generic equivalent to the antibiotic Achromycin V and adds to Heritage's robust portfolio of generic oral solid products.  Tetracycline capsules have been on the FDA drug shortage list for the past two years and Heritage is the first generic pharmaceutical manufacturer to reintroduce the product.

About Tetracycline HCl
Tetracycline HCl is indicated for the treatment of various bacterial infections.  The package insert, which is available at www.heritagepharma.com, contains detailed information about the indications, complete side effect profile and prescribing information.

About Heritage
Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the U.S. prescription drug market.  Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. Heritage's products cover a number of therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management.  Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace.   Let our formula of high quality and consistent supply work for you as we continue to provide affordable healthcare solutions to the U.S. consumer.


'/>"/>
SOURCE Heritage Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. George Rosenkranz to Receive 2013 Biotechnology Heritage Award
2. Heritage-DREAM, National Cancer Institute Breast Cancer Network Inference Prize Announced
3. Heritage Provider Network, UCLA and Open mHealth announce the launch of $100,000 mobile apps health prize challenge
4. MEI Pharmas Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
5. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
6. Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
7. The Growing Role of Medical Science Liaisons in the Pharmaceutical Industry
8. Sarissa Capital Issues Open Letter Regarding Astex Pharmaceuticals
9. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
10. Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
11. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit ... einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology:
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... media outlet with a clinician-based audience, will be participating in Rare Disease Day ... in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and ...
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
Breaking Medicine News(10 mins):